Cyclodextrin-Based Delivery Systems for Arthritic Diseases: From Development to Experimental Therapeutics.
Arthritics diseases, such as rheumatoid arthritis and osteoarthritis are chronic inflammatory and one of the most prevalent health conditions that cause disability (pain and functional limitation of joints). Despite the research advances, the treatment of those pathological conditions remains ineffective, since the pharmacological therapy is palliative, reducing only the symptoms and, in some cases, the chronic progression of the disease. In this context, the development of new formulations for controlled release would be interesting for reducing the number of injections and would also increase the patient compliance. In this article, we present a review of the cyclodextrin (CD)-based delivery systems focusing from conventional guest-host inclusion complexes and CD-polysulphates, until supramolecular architectures such as drug-CD-polymers conjugates, pseudorotaxanes, hydrogels as well as double-carrier systems and other systems. In particular, this article focuses the main CD-based delivery systems described in the literature emphasizing their possible administration by intra-articular route on the treatment of arthritic diseases, concentrating on their development and also performance as in vivo experimental therapeutic systems.
Monica Helena
MH
Monteiro Nascimento
Alessandra Cristina
AC
Santos Akkari
Kelly Cristina
KC
Freitas Mariano
Antonio Sergio
AS
Kimus Braz
Christiane Bertachini
CB
Lombello
Human and Natural Sciences Center, ABC Federal University - UFABC. Av. dos Estados, 5001, Bairro Bangu. Bloco A, Torre 3, Sala 623-3, Santo Andre, SP, Brazil. daniele.araujo@ufabc.edu.br.
Daniele Ribeiro
DR
de Araujo
D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology; D003505:Cyclodextrins / Q000737:chemistry*; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D007270:Injections, Intra-Articular; D010003:Osteoarthritis / Q000188:drug therapy / Q000473:pathology; D011108:Polymers / Q000737:chemistry
D018501:Antirheumatic Agents; D003505:Cyclodextrins; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011108:Polymers